LCI699-matching Placebo

DRUG3 trials

Sponsors

Novartis Pharmaceuticals, Novartis

Conditions

Essential HypertensionHypertension

Phase 2

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

CompletedNCT00758524

Novartis PharmaceuticalsEssential Hypertension

Start: 2008-09-11End: 2009-07-02Updated: 2021-07-06

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

CompletedNCT00817635

NovartisHypertension

Start: 2008-12-22End: 2009-10-13Updated: 2021-06-02

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

CompletedNCT00817414

NovartisHypertension

Start: 2009-01-14End: 2009-08-12Updated: 2021-06-02

Related Papers

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.

2011-10-10153 citations